Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine
Blood biomarkers, including neurofilament light chain (NfL), have garnered attention as potential indicators for chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting adverse effect of neurotoxic anticancer drugs. However, no blood biomarker has been established for routine application...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Toxics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2305-6304/11/12/1004 |
| _version_ | 1797379212254904320 |
|---|---|
| author | David Balayssac Julie Durif Céline Lambert Cristelle Dalbos Eric Chapuy Monique Etienne Claire Demiot Jérôme Busserolles Vincent Martin Vincent Sapin |
| author_facet | David Balayssac Julie Durif Céline Lambert Cristelle Dalbos Eric Chapuy Monique Etienne Claire Demiot Jérôme Busserolles Vincent Martin Vincent Sapin |
| author_sort | David Balayssac |
| collection | DOAJ |
| description | Blood biomarkers, including neurofilament light chain (NfL), have garnered attention as potential indicators for chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting adverse effect of neurotoxic anticancer drugs. However, no blood biomarker has been established for routine application or translational research. This pilot study aimed to evaluate a limited panel of blood biomarkers in rat models of CIPN and their correlations with neuropathic pain. CIPN models were induced through repeated injections of oxaliplatin, paclitaxel, bortezomib, and vincristine. Electronic von Frey testing was used to assess tactile allodynia. Post anticancer injections, serum concentrations of 31 proteins were measured. Allodynia thresholds decreased in anticancer-treated animals compared to controls. No consistent modifications were observed in the biomarkers across CIPN models. The most noteworthy biomarkers with increased concentrations in at least two CIPN models were NfL (paclitaxel, vincristine), MCP-1, and RANTES (oxaliplatin, vincristine). Vincristine-treated animals exhibited strong correlations between LIX, MCP-1, NfL, and VEGF concentrations and tactile allodynia thresholds. No single biomarker can be recommended as a unique indicator of CIPN-related pain. Because of the study limitations (single dose of each anticancer drug, young animals, and single time measurement of biomarkers), further investigations are necessary to define the kinetics, specificities, and sensitivities of MCP-1, RANTES, and NfL. |
| first_indexed | 2024-03-08T20:18:53Z |
| format | Article |
| id | doaj.art-28b835c8e1d84e2888d8a6ec346ad5c3 |
| institution | Directory Open Access Journal |
| issn | 2305-6304 |
| language | English |
| last_indexed | 2024-03-08T20:18:53Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxics |
| spelling | doaj.art-28b835c8e1d84e2888d8a6ec346ad5c32023-12-22T14:46:07ZengMDPI AGToxics2305-63042023-12-011112100410.3390/toxics11121004Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and VincristineDavid Balayssac0Julie Durif1Céline Lambert2Cristelle Dalbos3Eric Chapuy4Monique Etienne5Claire Demiot6Jérôme Busserolles7Vincent Martin8Vincent Sapin9Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceLaboratoire de Biochimie et de Génétique Moléculaire, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceUnité de Biostatistiques, Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceMetabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceUR 20218—Neuropathies et Innovations Thérapeutiques (NeurIT), Faculties of Medicine and Pharmacy, University of Limoges, F-87025 Limoges, FranceINSERM U1107 NEURO-DOL, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceMetabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceLaboratoire de Biochimie et de Génétique Moléculaire, CNRS, INSERM, iGReD, CHU Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, FranceBlood biomarkers, including neurofilament light chain (NfL), have garnered attention as potential indicators for chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting adverse effect of neurotoxic anticancer drugs. However, no blood biomarker has been established for routine application or translational research. This pilot study aimed to evaluate a limited panel of blood biomarkers in rat models of CIPN and their correlations with neuropathic pain. CIPN models were induced through repeated injections of oxaliplatin, paclitaxel, bortezomib, and vincristine. Electronic von Frey testing was used to assess tactile allodynia. Post anticancer injections, serum concentrations of 31 proteins were measured. Allodynia thresholds decreased in anticancer-treated animals compared to controls. No consistent modifications were observed in the biomarkers across CIPN models. The most noteworthy biomarkers with increased concentrations in at least two CIPN models were NfL (paclitaxel, vincristine), MCP-1, and RANTES (oxaliplatin, vincristine). Vincristine-treated animals exhibited strong correlations between LIX, MCP-1, NfL, and VEGF concentrations and tactile allodynia thresholds. No single biomarker can be recommended as a unique indicator of CIPN-related pain. Because of the study limitations (single dose of each anticancer drug, young animals, and single time measurement of biomarkers), further investigations are necessary to define the kinetics, specificities, and sensitivities of MCP-1, RANTES, and NfL.https://www.mdpi.com/2305-6304/11/12/1004chemotherapy-induced peripheral neuropathyoxaliplatinpaclitaxelbortezomibvincristineanimal model |
| spellingShingle | David Balayssac Julie Durif Céline Lambert Cristelle Dalbos Eric Chapuy Monique Etienne Claire Demiot Jérôme Busserolles Vincent Martin Vincent Sapin Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine Toxics chemotherapy-induced peripheral neuropathy oxaliplatin paclitaxel bortezomib vincristine animal model |
| title | Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine |
| title_full | Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine |
| title_fullStr | Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine |
| title_full_unstemmed | Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine |
| title_short | Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine |
| title_sort | exploring serum biomarkers for neuropathic pain in rat models of chemotherapy induced peripheral neuropathy a comparative pilot study with oxaliplatin paclitaxel bortezomib and vincristine |
| topic | chemotherapy-induced peripheral neuropathy oxaliplatin paclitaxel bortezomib vincristine animal model |
| url | https://www.mdpi.com/2305-6304/11/12/1004 |
| work_keys_str_mv | AT davidbalayssac exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT juliedurif exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT celinelambert exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT cristelledalbos exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT ericchapuy exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT moniqueetienne exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT clairedemiot exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT jeromebusserolles exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT vincentmartin exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine AT vincentsapin exploringserumbiomarkersforneuropathicpaininratmodelsofchemotherapyinducedperipheralneuropathyacomparativepilotstudywithoxaliplatinpaclitaxelbortezomibandvincristine |